Neurocrine Biosciences' potential shines with robust assets, strong pipeline, and growth opportunities. Learn more about NBIX ...

BMS swooped on Karuna towards the end of last year, shortly after AbbVie agreed an $8.7 billion deal to acquire Cerevel Therapeutics, another company developing a schizophrenia drug with a novel ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics in 2023 and the drug's approval last September ended a decades-long drought in new-mechanism therapies for ...

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies ...

Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.

Market: Open Tenaya Therapeutics, Inc. Common Stock (TNYA) Bid: $0.6005 X 600 Ask: $0.6033 X 452 Volume: 1,212,269 ...